Scilex Holding (SCLXW) Cash from Operations (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Cash from Operations of 1100000.0 in Q1 2026, up 106.3% quarter-over-quarter from 17471000.0 in Q4 2025, and down 81.69% on a YoY basis from 6007000.0 in Q1 2025.
Scilex Holding (SCLXW) Cash from Operations (2020 - 2026) Analysis & Trends
Scilex Holding's Cash from Operations history runs 7 years deep, the most recent figure standing at 1100000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 81.69% year-over-year to 1100000.0; the TTM figure through Mar 2026 stood at 1091000.0 (down 106.83% YoY), while the FY2025 annual figure was 3816000.0, down 80.28% from the prior year.
- Cash from Operations was 1100000.0 for Q1 2026 at Scilex Holding, up from 17471000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9391000.0 in Q1 2024 to a low of 17471000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 1041176.47 across 5 years, with a median of 2311000.0 in 2024.
- Biggest YoY gain for Cash from Operations was 1884.07% in 2022; the steepest drop was 2136.1% in 2022.
- A 5-year view of Cash from Operations shows it stood at 725000.0 in 2022, then tumbled by 643.45% to 5390000.0 in 2023, then jumped by 147.01% to 2534000.0 in 2024, then plunged by 789.46% to 17471000.0 in 2025, then jumped by 106.3% to 1100000.0 in 2026.
- The last three Cash from Operations figures came in at 1100000.0 (Q1 2026), 17471000.0 (Q4 2025), and 8187000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.82 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Dec 31, 2023 | -5.39 Mn |
| Dec 31, 2023 | -5.39 Mn |